A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in HR-Positive, HER2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.

CONCLUSION: Fulvestrant 500 mg is a feasible and promising hormonal maintenance strategy in ER-positive/HER2-negative advanced breast cancer patients who have no disease progression after first-line chemotherapy. PMID: 33245164 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33245164?dopt=Abstract

Source: The Oncologist - November 27, 2020 Category: Cancer & Oncology Authors: Xu F, Zheng Q, Xia W, Ouyang Q, Pang D, Yuan Z, Shi Y, Peng R, Lu Q, Wang S Tags: Oncologist Source Type: research